Core Insights - Medtronic is set to report earnings on August 19, 2025, with historical stock performance post-earnings being highly unpredictable, showing a 50% chance of positive returns and a median gain of 2.5%, while also experiencing a median loss of -3.8% in negative instances [4][8]. Financial Performance - Medtronic's current market capitalization stands at $119 billion, with the company generating $34 billion in revenue over the last twelve months, an operating profit of $6.5 billion, and a net income of $4.7 billion [5]. Stock Performance Comparison - Over the past five years, Medtronic's stock has underperformed compared to the S&P 500, with its share price declining from approximately $100 to $95, while the S&P 500 has increased by about 70% during the same period [3]. Earnings Forecast - The consensus forecast for the upcoming earnings report is $1.23 per share on sales of $8.37 billion, indicating flat earnings per share compared to the previous year but an increase in sales from $7.92 billion [4]. Historical Earnings Reaction - An analysis of the last five years shows that Medtronic has had 20 earnings observations, with a 50% hit rate for positive one-day returns, which drops to 42% when considering the last three years [8]. Trading Strategies - Two trading strategies are suggested: pre-earnings positioning based on historical odds and post-earnings positioning that utilizes the relationship between immediate and medium-term returns to inform trading decisions [6].

Group 1 - Medtronic's board of directors approved a cash dividend of $0.71 per ordinary share for the second quarter of fiscal year 2026 [1] - This dividend declaration aligns with the company's previous announcement of a dividend increase made in May 2025 [1] - Medtronic has a strong track record, being a member of the S&P 500 Dividend Aristocrats index, having increased its annual dividend for 48 consecutive years [1] Group 2 - Medtronic is headquartered in Galway, Ireland, and is recognized as a leading global healthcare technology company [2] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies and therapies [2] - Medtronic's mission focuses on alleviating pain, restoring health, and extending life through innovative healthcare solutions [2]

Core Viewpoint - Analysts expect Medtronic to report quarterly earnings of $1.23 per share, indicating no change from the previous year, with revenues projected at $8.37 billion, reflecting a 5.7% increase year-over-year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [1][2] Revenue Projections - Analysts predict 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' at $728.31 million, a year-over-year increase of 2.2% [4] - 'Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular' is expected to reach $631.16 million, reflecting a 2.5% increase [4] - 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' is forecasted at $1.20 billion, indicating a 5% increase [5] - 'Net Sales- U.S. Revenue' is estimated at $4.26 billion, suggesting a 4.3% year-over-year change [6] - 'Net Sales- ROW- Cardiovascular' is projected to reach $1.71 billion, reflecting a 6.6% increase [8] Specific Segment Insights - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is expected to be $332.01 million, indicating a 6.4% increase [7] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is estimated at $326.25 million, reflecting a 3.9% increase [7] - 'Net Sales- ROW- Medical Surgical- Surgical & Endoscopy' is projected at $960.12 million, indicating a 4.9% increase [8] Market Performance - Over the past month, Medtronic shares have recorded returns of 3.5%, aligning with the Zacks S&P 500 composite's performance [9]

Core Viewpoint - Orchestra BioMed announced the publication of clinical data demonstrating that AVIM therapy significantly improves cardiac function in patients with hypertension and diastolic dysfunction, which are key contributors to heart failure with preserved ejection fraction (HFpEF) [1][2]. Group 1: Clinical Data and Findings - The publication titled "Effects of AtrioVentricular Interval Modulation (AVIM) Therapy in Subjects with Hypertension and Diastolic Dysfunction" reports a retrospective treatment-blinded analysis of MODERATO II patients [2]. - AVIM therapy significantly reduced systolic blood pressure (SBP) and improved echocardiographic markers of diastolic dysfunction, which is a common comorbidity in patients with isolated systolic hypertension [2][7]. - Key findings include a reduction in office SBP by 12.1±12.8 mmHg and ambulatory SBP by 8.3±9.7 mmHg over six months, both statistically significant (p<0.01 vs baseline) [8]. Group 2: Expert Commentary - Dr. Marat Fudim emphasized the clinical link between long-standing hypertension, diastolic dysfunction, and the development of HFpEF, noting that AVIM therapy may address this unmet medical need by providing sustained blood pressure reductions and improving ventricular compliance [4]. - Dr. Avi Fischer highlighted the potential of AVIM therapy to offer a differentiated, device-based approach for earlier intervention in disease progression, targeting both elevated systolic blood pressure and impaired diastolic function [4]. Group 3: Ongoing Studies and Future Directions - AVIM therapy is currently being evaluated in the BACKBEAT global pivotal study, which aims to support potential U.S. regulatory approval for use in pacemaker-indicated patients with uncontrolled hypertension [4][11]. - The BACKBEAT study will assess the safety and efficacy of AVIM therapy in patients with systolic blood pressure above target despite anti-hypertensive medication [11].

Core Viewpoint - Medtronic's stock has declined approximately 33% since mid-2021, but this decline may be overdone given the company's strong operating history and commitment to rewarding investors [1] Group 1: Dividend Performance - Medtronic's current dividend yield is around 3.1%, significantly higher than the S&P 500's 1.2% and the average healthcare stock's 1.8% [3] - The company has increased its dividend annually for 48 consecutive years, nearing Dividend King status, indicating a robust business model [4] - Despite current challenges, Medtronic is expected to continue rewarding investors with reliable dividends [5] Group 2: Innovation and Growth Challenges - Medtronic faces challenges in introducing new products quickly due to the complexity of medical device development and regulatory processes [6] - The company is making progress in innovation, with surgical robots and other new products expected to gain traction over time [7] - Long-term investors should remain optimistic about Medtronic's potential for future growth [8] Group 3: Business Revamping - Medtronic is focusing on improving profitability by divesting from less profitable segments, which is a standard practice for large companies [9] - The planned spin-off of its diabetes business is expected to enhance profitability and free up capital for R&D or acquisitions [10] - While the diabetes spinoff may present short-term challenges, the long-term outlook for dividend investors remains positive [12]

Core Insights - Medtronic plc (MDT) is set to report its first-quarter fiscal 2026 results on August 19, with adjusted earnings in the last quarter exceeding estimates by 2.53% [1][2] - The Zacks Consensus Estimate for Q1 revenues is $8.37 billion, indicating a year-over-year growth of 5.7%, while earnings per share (EPS) is estimated at $1.23, flat compared to the previous year [2][12] - EPS estimates have declined by 6.8% over the past 90 days, reflecting challenges from rising costs and inflationary pressures [3][4] Financial Performance - Medtronic has consistently beaten earnings estimates in the last four quarters, with an average surprise of 2.21% [1] - The company’s adjusted gross margin decreased by 70 basis points year-over-year in Q4 fiscal 2025 due to foreign exchange impacts [9] - The company expects a 1-2% unfavorable impact on quarterly revenues from foreign exchange at recent rates [11] Business Segments and Growth Drivers - The separation of the Diabetes business, which accounted for about 8% of total revenue, may have affected quarterly performance [5][13] - Despite challenges, Medtronic has shown resilience with mid-single-digit organic revenue growth and strong performance in several segments, including pulse field ablation, TAVR, and neuromodulation [14][15] - The company is expected to report growth in its Neuromodulation segment, driven by closed-loop sensing technology [17] Market Position and Valuation - Medtronic's stock rose 9.3% in the fiscal first quarter, outperforming the industry and S&P 500 [25] - The company trades at a forward P/E ratio of 16.23, significantly below the industry average of 22.00 and the S&P 500's 21.19, indicating a potential undervaluation [26] - Medtronic's liquidity position is strong, with cash and cash equivalents of $8.97 billion against total debt of $28.5 billion [22][23] Strategic Outlook - The company is focusing on foundational changes, including improving global operations and investing in fast-growth MedTech markets [19][20] - Medtronic's highest growth opportunities are in markets growing faster than the overall company, particularly in Cardiac Ablation [21] - The ongoing transformation and exposure to strong secular growth markets position Medtronic for long-term growth despite macroeconomic headwinds [29]

Group 1: Dividend Kings Overview - Dividend Kings are companies that have increased their dividends annually for at least 50 consecutive years, showcasing resilience through multiple recessions [1] - Currently, there are only 55 companies classified as Dividend Kings, with more expected to join in the coming years [1] Group 2: ExxonMobil - ExxonMobil has increased its dividend for 42 consecutive years, the longest streak in the oil sector, with only 4% of S&P 500 companies achieving similar growth [2] - The company aims for $20 billion in earnings and $30 billion in cash flow by 2030, targeting compound annual growth rates of 10% for earnings and 8% for cash flow over the next five years [3] - ExxonMobil plans to invest $140 billion in high-return capital projects and its Permian Basin development, alongside achieving $7 billion in structural cost savings by 2030 [4] - The company is also investing in lower-carbon energy technologies, which could add $3 billion to earnings by 2030 and $13 billion by 2040, reinforcing its strong financial profile [5] Group 3: NNN REIT - NNN REIT achieved its 36th consecutive dividend increase, a milestone reached by only two other REITs and fewer than 80 publicly traded companies [6] - The REIT focuses on single-tenant net leased properties, generating reliable rental income through long-term leases in prime locations [7] - NNN REIT builds relationships with expanding retailers, facilitating new investment opportunities through sale-leaseback transactions, while maintaining a conservative financial profile [8] Group 4: Medtronic - Medtronic is close to becoming a Dividend King with 48 consecutive years of dividend growth, positioning itself well for future increases [9] - The company plans to separate its diabetes business within 18 months, allowing it to concentrate on its growing cardiovascular, neuroscience, and medical-surgical units [10] - Medtronic aims to capture a larger market share in these sectors through significant investments in research and development, supported by a strong balance sheet for potential acquisitions [11][12] Group 5: Conclusion - ExxonMobil, NNN REIT, and Medtronic are on track to become Dividend Kings, possessing the financial strength and growth potential to sustain dividend increases for years [13]

Core Viewpoint - Orchestra BioMed Holdings, Inc. announced a significant update to the BACKBEAT study protocol, approved by the FDA, which expands patient eligibility criteria for evaluating AVIM therapy in patients with uncontrolled hypertension who require pacemakers [1][5]. Summary by Relevant Sections Patient Eligibility Expansion - The updated protocol increases the eligible patient pool by more than 24-fold compared to the original protocol, supporting the company's target for mid-2026 completion of enrollment [2][5]. - New eligibility criteria include hypertensive patients who have received or are scheduled to receive a Medtronic Azure™ or Astra™ pacemaker, including device replacements [5][6]. Clinical Implications - The expanded criteria align the study population with the characteristics of the FDA Breakthrough Device Designation for AVIM therapy, potentially representing millions of U.S. patients needing better options for managing elevated systolic blood pressure [3][4]. - AVIM therapy is designed specifically for older, higher-risk hypertensive patients who may also require a pacemaker, reflecting its transformative potential [3][8]. Company Overview - Orchestra BioMed focuses on accelerating high-impact biomedical technologies through partnerships with leading medical device companies, with AVIM therapy as its lead product candidate for uncontrolled hypertension [4]. - The company has received four Breakthrough Device Designations from the FDA for its core programs, indicating significant potential to address unmet needs in cardiovascular care [4].

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 grew 15% year over year to $47.6 million, with adjusted EPS rising 14% to $1.6 per share, reflecting solid execution and continued operating leverage [32] - Royalty revenue increased 57% from the prior year to $36.4 million, underscoring the strength and momentum of partnered programs [32] - GAAP net income for the quarter was $4.8 million or $0.24 per diluted share, compared to a GAAP net loss of $51.9 million or $2.88 per share in the prior year period [38] Business Line Data and Key Metrics Changes - Key drivers of royalty revenue growth included strong performance from Varonis O2VARE, Trevyr's FILSPARI, Recordati's Carziva, and Merck's CapXiv and Vaxnuvanse [33] - Varonis reported a 45% sequential increase in Q2 2025 sales to $103 million, with expectations for continued strong launch trajectory [34] - FILSPARI showed strong commercial momentum, with Trevyr reporting Q2 sales in line with internal estimates, indicating robust year-over-year growth [34] Market Data and Key Metrics Changes - Merck's CapXiv generated $129 million in sales, a 21% sequential increase, while Vaxnuvanse generated $229 million in net sales, representing a 20% year-over-year increase [35] - Record ID reported sales of Carziva grew 12% in 2025, reaching €78.5 million, with Ligand earning a high teens royalty on Carziva sales [12] Company Strategy and Development Direction - The company aims to deliver profitable compounding growth by remaining disciplined in its investment approach and identifying high-quality assets that address significant unmet needs [21] - The strategic merger of Pylthos with Channel Therapeutics and a $40 million investment in Orchestra Biomed reflect the company's commitment to innovative therapies and expanding its portfolio [8][26] - The company is optimistic about the potential of its royalty assets, particularly with the expected blockbuster status of O2VARE by 2027 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the strong launch trajectories of therapies and the potential for significant revenue growth from O2VARE and FILSPARI [44] - The company anticipates that Merck's acquisition of Verona will accelerate the launch of O2VARE, enhancing its market potential [76] - Management acknowledged the ongoing pricing pressure in the pharmaceutical industry but emphasized the importance of investing in high clinical value drugs to navigate this environment [63] Other Important Information - The company ended the quarter with $245 million in cash and investments, with approximately $450 million in deployable capital factoring in its undrawn credit facility [32] - The deconsolidation of Peltos effective July 1 will impact future financial reporting, with the estimated fair value of Ligand's stake in Peltos at approximately $100 million [41] Q&A Session Summary Question: Expectations for the Peltos launch - Management is optimistic about the launch of ZELSUMI, citing strong demand and a capable commercial team [47][48] Question: Impact of Vilsparri REMS removal on uptake - The removal of REMS restrictions is expected to enhance uptake, particularly among earlier stage patients [50][51] Question: Guidance on revenue and EPS growth - Management explained that operating expenses are being cautiously managed, and tax rates are impacting net income due to increased foreign revenue [56][57] Question: Merck's ownership of Verona and its impact on O2VARE - Management believes Merck's global capabilities will accelerate O2VARE's rollout compared to its previous management by Verona [76] Question: Orchestra Biomed's commercialization pathway - Medtronic and Tarumo are the commercial partners for Orchestra Biomed's AVIM technology and Virtu SAB balloon, respectively [77]

Financial Performance & Guidance - Q2 2025 royalty revenue increased by 57% compared to Q2 2024, driven by Ohtuvayre, Filspari, Qarziba, Capvaxive and Vaxneuvance[3, 26] - Q2 2025 adjusted EPS grew 14% to $1.60[3, 24, 25] - The company increased revenue guidance for 2025 from $180 million-$200 million to $200 million-$225 million, a 13% increase[3, 24, 33] - Adjusted EPS guidance for 2025 was raised from $6.00-$6.25 to $6.70-$7.00 per diluted share, a 12% increase[3, 24, 33] Portfolio & Investments - Ligand has approximately 50% equity interest in Pelthos and is entitled to a 13% royalty on Zelsuvmi sales[3, 6] - The company committed $35 million in long-term capital for royalty interest in Orchestra BioMed's AVIM therapy and Virtue SAB and invested $5 million in equity private placement[3, 20, 21] - Merck is set to acquire Verona for $10 billion, which will impact Ligand's 3% royalty on Ohtuvayre[3, 4, 8] Strategic Outlook - The company anticipates a long-term royalty revenue CAGR of greater than 22%[3, 27] - Ohtuvayre peak-sales consensus updated from $1.2 billion in December 2024 to $3.4 billion in August 2025[30] - Ligand has ~$450 million in deployable capital as of June 30, 2025[3, 24]